Legend Biotech Corp. (LEGN) Report Interpretation

Overview

This earnings review examines Legend Biotech's 2Q26 return to profitability, the outlook for Carvykti-driven operating leverage, and upcoming in-vivo CAR-T clinical milestones. Goldman Sachs views FY26 adjusted profitability as on track and maintains its Buy rating.

Core views

Legend reported adjusted net income of US$63mn in 2Q26, its first quarter of profitability on both an adjusted and unadjusted basis, compared with a US$11mn net loss in 1Q26. Goldman Sachs attributes the improvement to stable collaboration income from inline Carvykti sales, US$61.4mn of licensing income from a commercial-expansion milestone payment, and a recovery in gross profit margin to 64.5% from 42.3% in 1Q26. The margin recovery reflected the unwinding of one-off manufacturing-expansion spending, while management also cited volume growth—primarily outside the US—and higher utilization. Management expects quarterly margin variability: gross margin is guided to around 50% in 3Q26 before recovering to the mid-50% range in 4Q26. Even with this expected fluctuation, management expects adjusted net income to stay positive in both quarters and reiterated confidence in achieving corporate-level adjusted profitability for FY26. Goldman Sachs estimates FY26 adjusted net income of US$84mn. Operating expenses were US$192mn, up 8% year on year but below Goldman Sachs' US$199mn estimate; research and development spending is shifting from Carvykti trials toward the in-vivo CAR-T pipeline. The report frames in-vivo CAR-T as the main pipeline focus as investor attention shifts beyond Carvykti. Management described the CEO change as a leadership transition rather than a strategic shift and reiterated that maximizing Carvykti and advancing in-vivo programs remain priorities. For LB2501, a CD19/CD20 in-vivo CAR-T program in non-Hodgkin lymphoma, management plans a US IND filing by year-end 2026 and expects an update from the China Phase 1 study at a major scientific conference in late 2H26, potentially ASH. Other cited catalysts are a Phase 1 update for LB2102, a DLL3 autologous CAR-T in relapsed/refractory small-cell lung cancer or large-cell neuroendocrine carcinoma, at WCLC26; initiation of a China investigator-initiated trial for LB2505, a BCMA in-vivo CAR-T in multiple myeloma; and CARTITUDE-5 results in 2027. Goldman Sachs revised its 12-month, risk-adjusted DCF-based target price to US$40.70 from US$40.50 after incorporating 2Q26 financials, near-term gross-margin assumptions and refined near-term operating-expense estimates. Its 2026E-2028E EPS forecasts changed from US$-0.24/US$0.20/US$0.61 to US$-0.13/US$0.30/US$0.60. The target price uses a 9% discount rate and 1% terminal growth rate. The institution continues to view Legend as undervalued, pointing to Carvykti's best-in-class BCMA CAR-T profile, expected global capacity expansion, Johnson & Johnson support, and potential upside from first-line multiple-myeloma treatment; it cites US$5.7bn of global peak sales for Carvykti.

Analysis framework

Goldman Sachs first links the quarterly profit swing to collaboration and licensing income, margin normalization and operating-cost control, then tests management's near-term profitability guidance against expected gross-margin variability. It separately assesses pipeline catalysts and updates earnings assumptions before revising its risk-adjusted DCF valuation.

Methodology notes

• Valuation methodsDCF (Discounted Cash Flow)

  Risk-adjusted 12-month discounted cash flow valuation

  The report derives its US$40.70 target price by discounting risk-adjusted future cash flows using a 9% discount rate and 1% terminal growth rate.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Legend Biotech Corp. (LEGN)

  Primary covered company; the report links its valuation and earnings outlook to Carvykti commercialization, capacity expansion and in-vivo CAR-T development.

  Strengths

  First profitable quarter, Carvykti's cited best-in-class BCMA CAR-T profile, Johnson & Johnson collaboration, and a broad CAR-T pipeline.

  Weaknesses

  Near-term gross margin is expected to fluctuate as manufacturing capacity expands.

  Comparison

  Goldman Sachs describes Carvykti as best-in-class in BCMA CAR-T and cites potential first-line multiple-myeloma upside.

  Risks

  Competition in late-line RRMM, capacity and accessibility barriers, talent retention challenges, and clinical development risk in first-line multiple myeloma.

Key data

• 2Q26 adjusted net incomeUS$63mnFirst profitable quarter on both adjusted and unadjusted bases, versus a US$11mn net loss in 1Q26.
• Gross profit margin64.5%Recovered from 42.3% in 1Q26; management guides around 50% in 3Q26 and the mid-50% range in 4Q26.
• Licensing incomeUS$61.4mnMilestone payment triggered by commercial expansion.
• Operating expensesUS$192mnUp 8% year on year and below Goldman Sachs' US$199mn estimate.
• FY26 adjusted net income estimateUS$84mnGoldman Sachs estimate supporting the view that FY26 profitability remains on track.
• 2026E-2028E EPS estimatesUS$-0.13 / US$0.30 / US$0.60Revised from US$-0.24 / US$0.20 / US$0.61.
• 12-month target priceUS$40.70Revised from US$40.50; based on a risk-adjusted DCF using a 9% discount rate and 1% terminal growth rate.

Impact & implications

Goldman Sachs sees the quarter as evidence that Carvykti-related income, improving utilization and controlled expenses can support FY26 adjusted profitability despite near-term gross-margin volatility. The report also places greater importance on forthcoming in-vivo CAR-T data and development milestones as drivers of the longer-term thesis.

Risks

• Increasing competition in relapsed/refractory multiple myeloma could pressure the late-line opportunity.
• Capacity expansion and patient accessibility could impede the sales ramp-up.
• Recruiting and retaining talent could create execution challenges.
• Clinical development in first-line multiple myeloma carries risk.

What to watch

• Whether adjusted net income remains positive in 3Q and 4Q26 despite management's expected gross-margin variability.
• Gross margin progression from approximately 50% in 3Q26 toward the mid-50% range in 4Q26.
• US IND filing and late-2H26 China Phase 1 data update for LB2501.
• WCLC26 Phase 1 update for LB2102 and initiation of the China investigator-initiated trial for LB2505.
• CARTITUDE-5 results expected in 2027.